当前位置： SCI文献检索 > INVESTIGATIONAL NEW DRUGS期刊下所有文献 > A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.

Abstract：

:The primary objective of this phase I study of LY2780301, a dual p70 S6 kinase and Akt inhibitor, was to determine the recommended phase II dose as a single agent in patients with advanced cancer. Secondary objectives included safety, pharmacokinetic, and pharmacodynamic analyses, and co-clinical analyses in Avatar models. Eligible patients received total daily doses of LY2780301 100-500 mg, given orally as a single dose or divided into 2 doses for 28-day cycles. Dose escalation followed 3 + 3 design. The primary pharmacodynamic endpoint was inhibition of S6 assessed by skin and tumor biopsy. Thirty-two patients were treated. Common toxicities possibly related to treatment included constipation (19 %), fatigue (13 %), nausea (9 %), and diarrhea (9 %). Grade 3/4 toxicities potentially related to treatment were anemia (n = 2), increased alanine aminotransferase/aspartate aminotransferase (ALT) (n = 1), and increased gamma-glutamyl transpeptidase (GGT) (n = 1). One patient experienced best overall response of prolonged stable disease for 6 cycles. Plasma exposures of LY2780301 exceeded predicted efficacious exposures, but were not dose proportional. Among patients receiving 500 mg daily >50 % exhibited reduced S6 in skin biopsies at Day 8 of treatment, but the effect was not maintained. Plasma concentrations of LY2780301 and/or its metabolites were not correlated with S6 expression in the epidermis. There was minimal antitumor activity against the model, CRC 019. Avatar models showed minimal pharmacodynamic effects consistent with the observed antitumor effects. This study suggests a dose of LY2780301 500 mg QD for future studies.

journal_name

Invest New Drugs

journal_title

Investigational new drugs

authors

Azaro A,Rodon J,Calles A,Braña I,Hidalgo M,Lopez-Casas PP,Munoz M,Westwood P,Miller J,Moser BA,Ohnmacht U,Bumgardner W,Benhadji KA,Calvo E

doi

10.1007/s10637-015-0241-7

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

710-9

issue

3

eissn

0167-6997

issn

1573-0646

journal_volume

33

pub_type

杂志文章,多中心研究

相关文献

INVESTIGATIONAL NEW DRUGS文献大全
  • Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.

    abstract：:Ergot alkaloids are psychoactive and vasoconstricting agents of the fungus Claviceps purpurea causing poisoning such as ergotism in medieval times (St. Anthony's Fire). This class of substances also inhibits tumor growth in vitro and in vivo, though the underlying mechanisms are unclear as yet. We investigated six erg...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-014-0168-4

    authors： Mrusek M,Seo EJ,Greten HJ,Simon M,Efferth T

    更新日期：2015-02-01 00:00:00

  • Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

    abstract：:Brequinar (DUP 785; NSC 368390) is a quinoline carboxylic acid derivative that inhibits pyrimidine synthesis at the level of dihydro-orotate dehydrogenase and revealed synergy with cisplatin in preclinical models. In this study investigating the pharmacokinetic and toxicity of brequinar in combination with cisplatin, ...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1016066529642

    authors： Burris HA 3rd,Raymond E,Awada A,Kuhn JG,O'Rourke TJ,Brentzel J,Lynch W,King SY,Brown TD,Von Hoff DD

    更新日期：1998-01-01 00:00:00

  • A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.

    abstract：PURPOSE:To compare two different infusion schedules of phenylacetate (PA) in patients with primary brain tumors and to assess the feasibility of the administration in a multi-institutional setting. PATIENTS AND METHODS:Adult patients with recurrent primary brain tumors were treated with PA on two different schedules. ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1023/a:1026299118067

    authors： Chang SM,Kuhn JG,Ian Robins H,Clifford Schold S,Spence AM,Berger MS,Mehta MP,Pollack I,Gilbert M,Prados MD

    更新日期：2003-11-01 00:00:00

  • Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.

    abstract：:Mitonafide is the lead compound of a new series of antitumor drugs, the 3-Nitronaphthalimides, which have shown antineoplastic activity in vitro as well as in vivo. This phase I Mitonafide study in non-small cell lung cancer using a 120-hour continuous infusion (120 h. C.I.) schedule of administration was designed to ...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00877242

    authors： Rosell R,Carles J,Abad A,Ribelles N,Barnadas A,Benavides A,Martin M

    更新日期：1992-08-01 00:00:00

  • Matrix metalloproteinase inhibitors: present achievements and future prospects.

    abstract：:Matrix metalloproteinases (MMPs) are a class of structurally related enzymes that function in the degradation of extracellular matrix proteins that constitute the pericellular connective tissue and play an important role in both normal and pathological tissue remodelling. Increased MMP activity is detected in a wide r...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1023/a:1005855905442

    authors： Denis LJ,Verweij J

    更新日期：1997-01-01 00:00:00

  • Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

    abstract：:Indibulin is a synthetic small molecule which antitumor activity is based upon destabilization of microtubules. The primary study objectives were to determine the impact of fasted and fed condition on pharmacokinetic parameters, as well as the maximum tolerated dose of the oral drinking solution of indibulin administe...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10637-006-9027-2

    authors： Kuppens IE,Witteveen PO,Schot M,Schuessler VM,Daehling A,Beijnen JH,Voest EE,Schellens JH

    更新日期：2007-06-01 00:00:00

  • 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.

    abstract：:9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in gastric cancer in a phase I study. We conducted a phase II study of 9-A...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/B:DRUG.0000026259.28395.c2

    authors： Kindler HL,Avadhani A,Wade-Oliver K,Karrison T,Mani S,Vokes EE

    更新日期：2004-08-01 00:00:00

  • Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

    abstract：PURPOSE:Cytotoxic and anti-angiogenic drugs are efficacious in malignancies. This trial was undertaken to evaluate the toxicity of a novel regimen combining docetaxel and lenalidomide. PATIENTS AND METHODS:Patients with advanced solid tumors were eligible. Docetaxel was administered on day 1, and lenalidomide was give...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-008-9200-x

    authors： Sanborn SL,Gibbons J,Krishnamurthi S,Brell JM,Dowlati A,Bokar JA,Nock C,Horvath N,Bako J,Remick SC,Cooney MM

    更新日期：2009-10-01 00:00:00

  • Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

    abstract：:Tyrosine kinase inhibitors (TKI) or monoclonal antibodies targeting EGFR, HER2 or VEGFR receptors have demonstrated substantial clinical benefit in patients with advanced breast cancer, colon cancer, head and neck cancer, non-small cell lung cancer, and renal cell carcinoma. Nevertheless, these drugs have some target ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9252-6

    authors： Bahleda R,Massard C,Soria JC,Izzedine H,Cohen A,Ederhy S

    更新日期：2010-06-01 00:00:00

  • Phase II trial with oral idarubicin in advanced breast cancer.

    abstract：:Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeuti...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00172014

    authors： Lopez M,Di Lauro L,Papaldo P,Lazzaro B,Ganzina F,Di Pietro N

    更新日期：1986-01-01 00:00:00

  • Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells.

    abstract：:Aberrant activation of the Wnt/β-catenin signaling pathway promotes osteosarcoma tumorigenesis and metastasis. In this study, we tested the hypothesis that osteosarcoma progression may be delayed by disrupting the Wnt/β-catenin pathway using small molecule inhibitors such as curcumin and PKF118-310. Effective inhibiti...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9311-z

    authors： Leow PC,Tian Q,Ong ZY,Yang Z,Ee PL

    更新日期：2010-12-01 00:00:00

  • Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

    abstract：:Background The hexapeptide 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) was isolated from a peptide library constructed to identify peptide-based transport inhibitors of multidrug resistance (MDR) efflux pumps including P-glycoprotein and Multidrug Resistance-associated Protein 1. 4A6 proved to be a subst...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-018-0569-x

    authors： Oerlemans R,Berkers CR,Assaraf YG,Scheffer GL,Peters GJ,Verbrugge SE,Cloos J,Slootstra J,Meloen RH,Shoemaker RH,Dijkmans BAC,Scheper RJ,Ovaa H,Jansen G

    更新日期：2018-10-01 00:00:00

  • Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.

    abstract：:A phase I trial of first-line vorinostat, an orally bio-available histone deacetylase inhibitor, in combination with capecitabine plus cisplatin (XP) was performed to assess recommend phase II trial dose in patients with advanced gastric cancer. Five dose levels of three-weekly vorinostat-XP were tested; vorinostat wa...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-013-9983-2

    authors： Yoo C,Ryu MH,Na YS,Ryoo BY,Lee CW,Maeng J,Kim SY,Koo DH,Park I,Kang YK

    更新日期：2014-04-01 00:00:00

  • A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.

    abstract：:Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 i.v. bolus daily x 5) with 5FU (425 mg/m2 i.v. bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, t...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1006484031959

    authors： Blanke CD,Stipanov M,Morrow J,Rothenberg M,Chinery R,Shyr Y,Coffey R,Johnson DH,Leach SD,Beauchamp RD

    更新日期：2001-01-01 00:00:00

  • Cellular pharmacology of fluorinated pyrimidines in vivo in man.

    abstract：:Fluorinated pyrimidines, particularly 5-fluorouracil (FUra), have been the subject of intense and almost continuous basic and clinical study since development in the late 1950's by Dr. Charles Heidelberger. Despite this intensive effort, the most important mechanisms by which FUra influences tumor growth in individual...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1007/BF00178188

    authors： Kovach JS,Beart RW Jr

    更新日期：1989-04-01 00:00:00

  • Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

    abstract：INTRODUCTION:This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins αVβ3 and αVβ5, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients (n = 140) wi...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10637-012-9842-6

    authors： Manegold C,Vansteenkiste J,Cardenal F,Schuette W,Woll PJ,Ulsperger E,Kerber A,Eckmayr J,von Pawel J

    更新日期：2013-02-01 00:00:00

  • Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells.

    abstract：:The anti-tumor properties of novel derivatives prepared from Aconitum C(20)-diterpenoid alkaloid, which show the least toxicity among the Aconitum alkaloids, were investigated in the Non-Hodgkin's lymphoma cell line Raji cells. Two novel Aconitum C(20)-diterpenoid alkaloid derivatives, 11-m-Trifluorometylbenzoyl (Mb)-...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9327-4

    authors： Hazawa M,Takahashi K,Wada K,Mori T,Kawahara N,Kashiwakura I

    更新日期：2011-02-01 00:00:00

  • A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.

    abstract：:Background PF-06650808 is a novel anti-Notch3 antibody-drug conjugate (ADC) able to deliver an auristatin-based cytotoxic payload to target cells. In this first-in-human, dose-finding, phase I study (NCT02129205), we investigated safety, pharmacokinetics, immunogenicity, and preliminary antitumor activity of single-ag...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10637-019-00754-y

    authors： Rosen LS,Wesolowski R,Baffa R,Liao KH,Hua SY,Gibson BL,Pirie-Shepherd S,Tolcher AW

    更新日期：2020-02-01 00:00:00

  • A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

    abstract：:Introduction BTH1677, a 1,3-1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with cetuximab/carboplatin/paclitaxel in untreated stage ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10637-017-0450-3

    authors： Thomas M,Sadjadian P,Kollmeier J,Lowe J,Mattson P,Trout JR,Gargano M,Patchen ML,Walsh R,Beliveau M,Marier JF,Bose N,Gorden K,Schneller F 3rd

    更新日期：2017-06-01 00:00:00

  • Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

    abstract：:Alectinib, the second generation anaplastic lymphoma kinase (ALK) inhibitor, has significant potency in patients with ALK rearrangement positive non-small cell lung cancer (NSCLC), and its toxicity is generally well tolerable. We report a patient who developed severe acute interstitial lung disease after alectinib tre...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-015-0284-9

    authors： Yamamoto Y,Okamoto I,Otsubo K,Iwama E,Hamada N,Harada T,Takayama K,Nakanishi Y

    更新日期：2015-10-01 00:00:00

  • Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities.

    abstract：:Lactoferrin has gained extensive attention due to its ample biological properties. In this study, recombinant human lactoferrin carrying humanized glycosylation (rhLf-h-glycan) expressed in the yeast Pichia pastoris SuperMan5, which is genetically glycoengineered to efficiently produce functional humanized glycoprotei...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-01020-2

    authors： Nakamura-Bencomo S,Gutierrez DA,Robles-Escajeda E,Iglesias-Figueroa B,Siqueiros-Cendón TS,Espinoza-Sánchez EA,Arévalo-Gallegos S,Aguilera RJ,Rascón-Cruz Q,Varela-Ramirez A

    更新日期：2020-10-16 00:00:00

  • In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay.

    abstract：:In vitro antitumor effects of human recombinant tumor necrotizing factor (rH-TNF) were examined against nine lung cancer cell lines including six non small and three small cell lung cancer, four stomach cancer cell lines and 30 freshly isolated lung cancer cell samples by the human tumor clonogenic assay. rH-TNF did n...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00169974

    authors： Sasaki Y,Kanzawa F,Takahashi H,Matsushima Y,Nakano H,Nakagawa K,Hong WS,Minato K,Fujiwara Y,Saijo N

    更新日期：1987-12-01 00:00:00

  • A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

    abstract：BACKGROUND:We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XEL...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-009-9363-0

    authors： Kim C,Lee JL,Ryu MH,Chang HM,Kim TW,Lim HY,Kang HJ,Park YS,Ryoo BY,Kang YK

    更新日期：2011-04-01 00:00:00

  • High incidence of local venous reactions to esorubicin.

    abstract：:A retrospective analysis was performed on the medical charts of 160 cancer patients who received esorubicin (ESO or 4'deoxydoxorubicin) in a Phase I clinical trial. The purpose of the review was to characterize the incidence of local venous reactions to this investigational doxorubicin (DOX) analog. The impact of prop...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00217666

    authors： Lee KM,Dorr RT,Robertone A

    更新日期：1987-01-01 00:00:00

  • A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

    abstract：:Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in recurrent malignant glioma to determine the maximum tolerated dose ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-00950-1

    authors： Reardon DA,Desjardins A,Rixe O,Cloughesy T,Alekar S,Williams JH,Li R,Taylor CT,Lassman AB

    更新日期：2020-12-01 00:00:00

  • Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.

    abstract：:Epidermal growth factor receptor (EGFR) gene mutations activate the KRAS-RAF-MEK-ERK pathway in lung cancer cells. EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib induce apoptosis of cancer cells, but prolonged treatment is often associated with acquired resistance. Here, we identified a novel MEK1/2 inhibito...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-013-0030-0

    authors： Song JY,Kim CS,Lee JH,Jang SJ,Lee SW,Hwang JJ,Lim C,Lee G,Seo J,Cho SY,Choi J

    更新日期：2013-12-01 00:00:00

  • Gemcitabine and radiosensitization in human tumor cells.

    abstract：:Gemcitabine is a nucleoside analogue with excellent clinical activity against solid tumors. Within the cell, gemcitabine is rapidly phosphorylated to its active di- and triphosphate metabolites. Cytotoxicity with gemcitabine appears to be related to multiple effects on DNA replication, where gemcitabine triphosphate c...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1007/BF00194528

    authors： Shewach DS,Lawrence TS

    更新日期：1996-01-01 00:00:00

  • Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.

    abstract：:Rolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy. Her...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10637-018-0638-1

    authors： Zhang ZY,Wang J,Kansra V,Wang X

    更新日期：2019-02-01 00:00:00

  • Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

    abstract：:Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especially for a splice version of the Androgen Receptor (AR) AR-V7, which is a variant ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1007/s10637-018-0653-2

    authors： Sobhani N,Generali D,D'Angelo A,Aieta M,Roviello G

    更新日期：2018-12-01 00:00:00

  • Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

    abstract：BACKGROUND:Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS. METHODS:Patients with advanced, recurrent, or ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-006-9035-2

    authors： Suppiah R,Wood L,Elson P,Budd GT

    更新日期：2006-11-01 00:00:00